# Boosting Cuproptosis in Breast Cancer Therapy via Photodynamic Treatment With a New Liposome

**Authors:** Jie Yu, Ning Sun, Limei You, Jialing Liu, Mengna Niu, Jiacheng Shi, Weixin Chen, Futong Li, Shengbao Wang, Jiaqi Liu

PMC · DOI: 10.1096/fba.2025-00280 · FASEB BioAdvances · 2026-02-17

## TL;DR

This study explores combining photodynamic therapy with cuproptosis to enhance breast cancer treatment, showing promising results in both lab and animal experiments.

## Contribution

A novel liposome combining photodynamic therapy and cuproptosis inducers is developed for synergistic breast cancer treatment.

## Key findings

- The liposome formulation effectively induced cuproptosis and produced reactive oxygen species under laser irradiation.
- The combination therapy showed significant tumor inhibition in both in vitro and in vivo experiments.
- The treatment was safe, with no significant changes in body weight observed in the animal model.

## Abstract

Breast cancer (BC) is one of the most common cancers in women around the world, and utilizing a combined approach is a crucial strategy. Induction of cuproptosis in tumor cells is a novel antitumor approach, though its standalone efficacy remains unclear. In this study, we prepared a novel liposome loaded with the photosensitizer indocyanine Green (ICG) and the cuproptosis inducer elesclomol‐Cu (ES‐Cu) to examine the synergistic effects of photodynamic‐cuproptosis treatment on BC. The cuproptosis inducer ES‐Cu and the photosensitizer ICG were encapsulated in nanoliposomes with a membrane hydration approach and then validated in vitro and in vivo. JC‐1, MDA, GSH, and other cuproptosis‐related indicators were used to confirm the ability of PDT to enhance ES‐Cu‐induced cuproptosis in MCF‐7 breast cancer cells. For confirming the cytotoxic impact of PDT in conjunction with the cuproptosis inducer, tests for CCK‐8 and cell death staining were performed. The drugs were administered to animals via tail vein injection to observe their tumor inhibition effects in vivo. Their safety was assessed by monitoring changes in body weight. The average particle size of liposomes loaded with ES‐Cu and ICG was 208.3 ± 1.07 nm, exhibiting a consistent nanospherical morphology. ICG produced cytotoxic reactive oxygen species (ROS) that enhanced ES‐Cu‐induced cell cupping under NIR laser irradiation. The therapeutic effect of the synergistic treatment combining PDT and cuproptosis was validated in both in vitro and in vivo experiments. This investigation proved that PDT markedly augments the ES‐Cu‐induced cuproptosis in breast cancer cells, demonstrating a synergistic therapeutic effect. This synergistic effect presents a novel therapy approach for BC with substantial practical application potential.

## Linked entities

- **Chemicals:** indocyanine Green (PubChem CID 5282412), elesclomol-Cu (PubChem CID 86289903)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** Dlat (dihydrolipoamide S-acetyltransferase) [NCBI Gene 235339] {aka 6332404G05Rik, DLTA, PDC-E2}, Fdx1 (ferredoxin 1) [NCBI Gene 14148], FDX1 (ferredoxin 1) [NCBI Gene 2230] {aka ADX, FDX, LOH11CR1D}, DLAT (dihydrolipoamide S-acetyltransferase) [NCBI Gene 1737] {aka DLTA, E2, PBC, PDC-E2, PDCE2}, PDP1 (pyruvate dehydrogenase phosphatase catalytic subunit 1) [NCBI Gene 54704] {aka PDH, PDP, PDPC, PDPC 1, PPM2A, PPM2C}, LIAS (lipoic acid synthetase) [NCBI Gene 11019] {aka HGCLAS, HUSSY-01, LAS, LIP1, LS, PDHLD}
- **Diseases:** Cancer (MESH:D009369), mitochondrial damage (MESH:D028361), hypoxic (MESH:D002534), Cytotoxicity (MESH:D064420), HCC (MESH:D006528), necrosis (MESH:D009336), BC (MESH:D001943)
- **Chemicals:** LA (MESH:D008063), MDA (MESH:D015104), nitrogen (MESH:D009584), PI (MESH:D010716), DSPC (MESH:C010942), calcein-AM (MESH:C085925), Chol (MESH:D002784), Cu (MESH:D003300), DTNB (MESH:D004228), ES (MESH:C512195), DCFH-DA (MESH:C029569), Fe-S (MESH:D007501), CCK-8 (MESH:D012844), water (MESH:D014867), TCA (MESH:D014238), PC (MESH:C053518), ICG (MESH:D007208), MDA (MESH:D008315), NADPH (MESH:D009249), JC-1 (MESH:C068624), Cu2+ (-), propidium iodide (MESH:D011419), PE (MESH:C483858), H&amp;E (MESH:D006371), TNB (MESH:D014302), lecithin (MESH:D054709), ROS (MESH:D017382), 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (poly (ethylene glycol))-2000] (MESH:C519184), PBS (MESH:D007854), CHCl3 (MESH:D002725), lipid (MESH:D008055), AM/PI (MESH:C058215), GSH (MESH:D005978), CO2 (MESH:D002245)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** ES-Cu — Callorhinus ursinus (Northern fur seal), Finite cell line (CVCL_S386), MCF-7-luc — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_5J36), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), Hepa1-6 — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_0327), MCF-7 BC — Homo sapiens (Human), Transformed cell line (CVCL_WC49)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913696/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913696/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913696/full.md

---
Source: https://tomesphere.com/paper/PMC12913696